Sign in Subscribe

approved

A collection of 2 issues

KRAS G12C inhibitor Krazati fails confirmatory phase 3 trial

Skip to content The CRC Digest KRAS G12C inhibitor Krazati fails confirmatory phase 3 trial The Krystal-10 study did not meet primary endpoints in 461 patients with KRAS G12C-mutated metastatic colorectal cancer, raising questions about the drug's path to full FDA approval. (Fierce Pharma) This content is informational

ColoSense RNA-Based At-Home Test

Skip to content The CRC Digest ColoSense RNA-Based At-Home Test First FDA-approved RNA-based at-home screening test now available nationwide through Labcorp. This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com